361 related articles for article (PubMed ID: 35038570)
21. Subcutaneous Versus Transvenous Implantable Defibrillator Therapy: A Meta-Analysis of Case-Control Studies.
Basu-Ray I; Liu J; Jia X; Gold M; Ellenbogen K; DiNicolantonio J; Komócsi A; Vorobcsuk A; Kim J; Afshar H; Lam W; Mathuria N; Razavi M; Rasekh A; Saeed M
JACC Clin Electrophysiol; 2017 Dec; 3(13):1475-1483. PubMed ID: 29759827
[TBL] [Abstract][Full Text] [Related]
22. Subcutaneous Versus Transvenous Implantable Defibrillator Therapy: A Systematic Review and Meta-Analysis of Randomized Trials and Propensity Score-Matched Studies.
Fong KY; Ng CJR; Wang Y; Yeo C; Tan VH
J Am Heart Assoc; 2022 Jun; 11(11):e024756. PubMed ID: 35656975
[TBL] [Abstract][Full Text] [Related]
23. Implantable cardioverter defibrillator therapy and sudden death risk stratification in hypertrophic cardiomyopathy patients with midventricular obstruction: A single-center experience.
Maeda R; Minami Y; Haruki S; Kanbayashi K; Itani R; Suzuki A; Ejima K; Shiga T; Shoda M; Hagiwara N
Int J Cardiol; 2016 Jul; 214():419-22. PubMed ID: 27088403
[TBL] [Abstract][Full Text] [Related]
24. Candidacy and long-term outcomes of subcutaneous implantable cardioverter-defibrillators in current practice in patients with hypertrophic cardiomyopathy.
Rella V; Maurizi N; Bernardini A; Brasca FM; Salerno S; Meda M; Mariani D; Torchio M; Ravaro S; Cerea P; Castelletti S; Fumagalli C; Conte G; Auricchio A; Girolami F; Pieragnoli P; Carrassa GM; Parati G; Olivotto I; Perego GB; Cecchi F; Crotti L
Int J Cardiol; 2024 Aug; 409():132202. PubMed ID: 38795975
[TBL] [Abstract][Full Text] [Related]
25. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
[TBL] [Abstract][Full Text] [Related]
26. Risk Markers and Appropriate Implantable Defibrillator Therapy in Hypertrophic Cardiomyopathy.
Magnusson P; Gadler F; Liv P; Mörner S
Pacing Clin Electrophysiol; 2016 Mar; 39(3):291-301. PubMed ID: 26681505
[TBL] [Abstract][Full Text] [Related]
27. Ventricular arrhythmias in patients with hypertrophic cardiomyopathy: Prevalence, distribution, predictors, and outcome.
Segev A; Wasserstrum Y; Arad M; Larrañaga-Moreira JM; Martinez-Veira C; Barriales-Villa R; Sabbag A
Heart Rhythm; 2023 Oct; 20(10):1385-1392. PubMed ID: 37385464
[TBL] [Abstract][Full Text] [Related]
28. Comparison of transvenous vs subcutaneous defibrillator therapy in patients with cardiac arrhythmia syndromes and genetic cardiomyopathies.
Kuschyk J; Müller-Leisse J; Duncker D; Tülümen E; Fastenrath F; Fastner C; Kruska M; Akin I; Liebe V; Borggrefe M; Veltmann C; Rudic B
Int J Cardiol; 2021 Jan; 323():100-105. PubMed ID: 32871189
[TBL] [Abstract][Full Text] [Related]
29. Subcutaneous versus transvenous implantable defibrillator: An updated meta-analysis.
Rordorf R; Casula M; Pezza L; Fortuni F; Sanzo A; Savastano S; Vicentini A
Heart Rhythm; 2021 Mar; 18(3):382-391. PubMed ID: 33212250
[TBL] [Abstract][Full Text] [Related]
30. Importance of newer cardiac magnetic resonance-based risk markers for sudden death prevention in hypertrophic cardiomyopathy: An international multicenter study.
Rowin EJ; Maron MS; Adler A; Albano AJ; Varnava AM; Spears D; Marsy D; Heitner SB; Cohen E; Leong KMW; Winters SL; Martinez MW; Koethe BC; Rakowski H; Maron BJ
Heart Rhythm; 2022 May; 19(5):782-789. PubMed ID: 34933112
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of subcutaneous implantable cardioverter-defibrillator candidacy based on template ECG screening in patients with hypertrophic cardiomyopathy.
Maurizi N; Olivotto I; Olde Nordkamp LR; Baldini K; Fumagalli C; Brouwer TF; Knops RE; Cecchi F
Heart Rhythm; 2016 Feb; 13(2):457-63. PubMed ID: 26362577
[TBL] [Abstract][Full Text] [Related]
32. QRS Fragmentation and QTc Duration Relate to Malignant Ventricular Tachyarrhythmias and Sudden Cardiac Death in Patients with Hypertrophic Cardiomyopathy.
Debonnaire P; Katsanos S; Joyce E; VAN DEN Brink OV; Atsma DE; Schalij MJ; Bax JJ; Delgado V; Marsan NA
J Cardiovasc Electrophysiol; 2015 May; 26(5):547-55. PubMed ID: 25648421
[TBL] [Abstract][Full Text] [Related]
33. Subcutaneous versus transvenous implantable cardioverter-defibrillator among drug-induced type-1 ECG pattern Brugada syndrome: a propensity score matching analysis from IBRYD study.
Russo V; Caturano A; Guerra F; Migliore F; Mascia G; Rossi A; Nesti M; Santobuono VE; Attena E; Tola G; Sciarra L; Conte G; Paoletti Perini A; Francia P; Dendramis G; Palamà Z; Albani S; Ottonelli Ghidini A; Calò L; D'Onofrio A; Baldi E;
Heart Vessels; 2023 May; 38(5):680-688. PubMed ID: 36418560
[TBL] [Abstract][Full Text] [Related]
34. Risk of Sudden Death in Patients With RASopathy Hypertrophic Cardiomyopathy.
Lynch A; Tatangelo M; Ahuja S; Steve Fan CP; Min S; Lafreniere-Roula M; Papaz T; Zhou V; Armstrong K; Aziz PF; Benson LN; Butts R; Dragulescu A; Gardin L; Godown J; Jeewa A; Kantor PF; Kaufman BD; Lal AK; Parent JJ; Richmond M; Russell MW; Balaji S; Stephenson EA; Villa C; Jefferies JL; Whitehill R; Conway J; Howard TS; Nakano SJ; Rossano J; Weintraub RG; Mital S
J Am Coll Cardiol; 2023 Mar; 81(11):1035-1045. PubMed ID: 36922089
[TBL] [Abstract][Full Text] [Related]
35. Sudden death related cardiomyopathies - Hypertrophic cardiomyopathy.
Goff ZD; Calkins H
Prog Cardiovasc Dis; 2019; 62(3):212-216. PubMed ID: 31004609
[TBL] [Abstract][Full Text] [Related]
36. Subcutaneous versus transvenous implantable cardioverter defibrillators in children and young adults: A meta-analysis.
Vetta G; Parlavecchio A; Magnocavallo M; Valente D; Caminiti R; Polselli M; Vetta F; Cirone D; Cauti FM; Crea P; Rossi P; Chierchia GB; Bianchi S; de Asmundis C; Natale A; Della Rocca DG
Pacing Clin Electrophysiol; 2022 Dec; 45(12):1409-1414. PubMed ID: 36214206
[TBL] [Abstract][Full Text] [Related]
37. Transvenous versus subcutaneous implantable cardioverter defibrillators in young cardiac arrest survivors.
Morton MB; Mariani JA; Kistler PM; Patel H; Voskoboinik A
Intern Med J; 2023 Nov; 53(11):1956-1962. PubMed ID: 37929818
[TBL] [Abstract][Full Text] [Related]
38. Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: Twenty years with the implantable cardioverter-defibrillator.
Maron BJ; Rowin EJ; Maron MS
Heart Rhythm; 2021 Jun; 18(6):1012-1023. PubMed ID: 33508516
[TBL] [Abstract][Full Text] [Related]
39. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy.
Cuoco FA; Spencer WH; Fernandes VL; Nielsen CD; Nagueh S; Sturdivant JL; Leman RB; Wharton JM; Gold MR
J Am Coll Cardiol; 2008 Nov; 52(21):1718-23. PubMed ID: 19007692
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of subcutaneous implantable cardioverter-defibrillator testing in patients with hypertrophic cardiomyopathy.
Maurizi N; Tanini I; Olivotto I; Amendola E; Limongelli G; Losi MA; Allocca G; Perego GB; Pieragnoli P; Ricciardi G; De Filippo P; Ferrari P; Quarta G; Viani S; Rapacciuolo A; Bongiorni MG; Cecchi F
Int J Cardiol; 2017 Mar; 231():115-119. PubMed ID: 28073660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
